Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis [0.03%]
免疫检查点抑制剂和抗体药物偶联物相关肺炎的异同性叙述性综述
Ruiting Tan,Fangfei Qian,Yao Zhang et al.
Ruiting Tan et al.
Background and objective: The adverse events (AEs) associated with immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) are clinically significant. The early recognition and effective management of AEs ...
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling [0.03%]
DNA低甲基化激活的PRAME通过ZNF740和PI3K/AKT/mTOR信号驱动早期肺腺癌复发
Guo-Nian Zhu,Qian Zheng,Pan Yang et al.
Guo-Nian Zhu et al.
Background: Lung adenocarcinoma (LUAD) represents a major clinical challenge due to its high recurrence and metastasis rates, with the underlying molecular mechanisms yet to be fully elucidated. Despite therapeutic advanc...
From biology to the clinic: research evidence and therapeutic advances of TROP2-targeted antibody-drug conjugates in small cell lung cancer [0.03%]
从生物学至临床：小细胞肺癌TROP2靶向抗体药物偶联物的研究证据和治疗进展
Haoyu Lu,Meiying Zhu,Yaning Luo et al.
Haoyu Lu et al.
Trophoblast cell surface antigen 2 (TROP2) is a type I transmembrane glycoprotein that was initially identified in studies related to trophoblastic cells and has been implicated in epithelial cell proliferation and the maintenance of cellul...
Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib [0.03%]
恩特雷廷 ib治疗ROS1 重排晚期非小细胞肺癌的PD-L1表达与临床结果之间的关联
Lixuan Chen,Wenhui Shi,Zhengqi Cao et al.
Lixuan Chen et al.
Background: In patients with advanced ROS1 rearrangement-positive non-small cell lung cancer (NSCLC), the relationship between programmed death ligand 1 (PD-L1) expression and the efficacy of tyrosine kinase inhibitors (T...
Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon T751_I759delinsAsp EGFR-mutant lung adenocarcinoma: a case report [0.03%]
罕见T751_I759delinsAsp表皮生长因子受体突变肺腺癌患者奥希替尼耐药后接受化疗联合安维汀治疗获得长期完全代谢缓解伴严重皮肤毒性的病例报告
Jean-Baptiste Barbe-Richaud,Erwan Pencreach,Roland Schott et al.
Jean-Baptiste Barbe-Richaud et al.
Background: Amivantamab, an epidermal growth factor receptor-MNNG-HOS transforming gene (EGFR-MET) bispecific antibody with immune cell-directing activity, plus platinum-based polychemotherapy improved survival outcomes i...
LUADnet: a deep learning model for prediction of clinical outcomes in lung adenocarcinoma based on gene expression signatures [0.03%]
基于基因表达谱的肺腺癌临床预后深度学习模型LUADnet
Cheng Cheng,Zhanlue Liang,Renjie Xu et al.
Cheng Cheng et al.
Background: Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer (NSCLC), and immunochemotherapy is widely utilized in its treatment. However, there are several drawbacks, including immun...
Accelerating tumor evolution and enhancing immunotherapy efficacy in lung adenocarcinoma based on EXO1 inhibition [0.03%]
基于EXO1抑制的肺腺癌肿瘤加速进化和增强免疫治疗效力的研究
Xianfei Zhang,Liangjiao Yao,Zhengxin Yin et al.
Xianfei Zhang et al.
Background: Emerging evidence highlights defects in DNA damage repair as critical modulators of tumor immunogenicity, yet the mechanistic interplay between repair pathway dynamics and immune checkpoint inhibitor efficacy ...
The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies [0.03%]
表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的耐药机制及应对策略研究
Shuotong Liu,Linsen Zhou,Yongze He et al.
Shuotong Liu et al.
Lung cancer remains the leading cause of global cancer-related mortality, with non-small cell lung cancer (NSCLC) constituting the predominant histological subtype. The discovery of epidermal growth factor receptor (EGFR) as a driver oncoge...
Deep learning model based on automated CT image segmentation for predicting the optimal radiotherapy protocol in limited-stage small cell lung cancer patients: a multicenter study [0.03%]
基于自动化CT图像分割的深度学习模型预测小细胞肺癌局限期患者最优放疗方案的多中心研究
Junfeng Zhao,Zongqian Yuan,Jinquan Yao et al.
Junfeng Zhao et al.
Background: Radiotherapy combined with chemotherapy is the standard treatment regimen for patients with limited-stage small cell lung cancer (LS-SCLC), but the optimal radiotherapy regimen for these patients remains uncle...
Novel lipid metabolism-related gene signature associated with clinical and immune features in lung adenocarcinoma patients experiencing lymph node metastasis [0.03%]
与肺癌淋巴结转移患者临床和免疫特征相关的新型脂质代谢相关基因签名
Shen Lao,Zisheng Chen,Yuan Zhang et al.
Shen Lao et al.
Background: Research has increasingly shown that lipid metabolism contributes to lymph node metastasis (LNM) and the progression of cancer. This study investigates the role of lipid metabolism in LNM of lung adenocarcinom...